Peptide library › Heart & blood
Enlicitide
Also known as Lipfendra, MK-0616
First daily tablet that blocks PCSK9 to lower LDL ("bad") cholesterol, a job that previously needed injections.
What people use it for
- High LDL cholesterol
What Enlicitide does in the body
A ring-shaped (macrocyclic) peptide built to survive digestion. It blocks PCSK9, a protein that destroys the liver's LDL receptors, so the liver keeps more receptors and clears more LDL cholesterol from the blood.
Strength of evidence
Strong: Phase 3 trials lowered LDL cholesterol by about 60%.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Generally well tolerated in trials
- Mild stomach upset
- Long-term effects still being followed
Who should avoid it or take extra care
- Pregnancy or breastfeeding, unless a specialist advises it
- Anyone not prescribed it
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved as Lipfendra, a once-daily tablet. Prescription only.
How it's taken
Route: Tablet by mouth, once daily
How long it lasts (half-life): Supports once-daily dosing
Latest research & news
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Clinical trial · Completed · Phase 3 · Updated · ClinicalTrials.gov · 17 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Enlicitide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Enlicitide in Fiala How to installMore in Heart & blood
- Angiotensin IIIntensive-care drip that raises dangerously low blood pressure in shock when other drugs aren't enough.
- BivalirudinShort-acting blood thinner given by drip during heart procedures such as stenting.
- DesirudinLab-made leech-derived blood thinner once used to prevent clots after hip replacement; now discontinued in the US.
- EptifibatideHospital drip that stops platelets clumping during heart attacks and stenting.
- NesiritideLab-made heart hormone (BNP) once used by drip for sudden heart failure; now largely withdrawn.
- VasopressinNatural hormone given by drip in intensive care to raise blood pressure in shock.
- SelepressinExperimental vasopressin-like drug for septic shock that failed its main trial.
- DesmopressinSynthetic version of the water-retaining hormone, used for bedwetting, frequent night-time urination, diabetes insipidus and some bleeding disorders.
- TerlipressinHospital drug that improves kidney function in hepatorenal syndrome, a kidney failure caused by severe liver disease.
- RusfertideWeekly injection that mimics the iron hormone hepcidin to control red blood cell overproduction in polycythemia vera.
- PegcetacoplanComplement blocker used for the rare blood disease PNH (as an infusion under the skin) and for geographic atrophy in the eye (as an eye injection).